Posaconazole Type of group

2 trials

Sponsors

SCHERING PLOUGH DEL PERU S.A.,, Merck Sharp & Dohme Corp., una subsidiaria de Merck & Co. Inc.,

Unknown Phase

Limited Access Protocol of Posaconazole in Invasive Fungal Infections Study PO2095

Active, not recruitingPER-028-03

SCHERING PLOUGH DEL PERU S.A.,

Target: 4Updated: 2023-09-04

POSACONAZOLE (MK-5592) IV AND ORAL IN CHILDREN WITH INVASIVE ASPERGILLOSIS.

RecruitingPER-039-19

Merck Sharp & Dohme Corp., una subsidiaria de Merck & Co. Inc.,

Start: 2019-04-13Target: 5Updated: 2024-08-20